FDA accepts Enzychem’s IND for trial of Covid-19 treatment candidate

FDA accepts Enzychem’s IND for trial of Covid-19 treatment candidate

Source: 
Pharmaceutical Business Review
snippet: 


The US Food and Drug Administration (FDA) has accepted Enzychem Lifescience’s investigational new drug application (IND) to assess its EC-18 therapeutic candidate for the prevention of acute respiratory disease syndrome (ARDS) due to Covid-19 pneumonia.